Therapeutic Asset Ratings
171 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Palonosetron
Chemotherapy-induced Nausea and Vomiting
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
A
(82)
Acetylsalicylic Acid
Brain Infarction
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
BBB
(75)
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Chemotherapy-induced Nausea and Vomiting
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
BBB
(75)
Selinexor
DLBCL
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
BBB
(72)
LECANEMAB
Alzheimer's Disease
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
BB
(71)
17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
Chronic Pain
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
BB
(70)
Cyclophosphamide
Breast Adenocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P3
BB
(70)
Evomela
Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
BB
(67)
Compound Edaravone
Stroke
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
BB
(66)
Cyclophosphamide
Primary Peritoneal Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P3
BB
(66)
DEXAMETHASONE
Nausea and Vomiting Caused by Chemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University
P3
BB
(66)
LECANEMAB
Alzheimer Disease (AD)
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
BB
(65)
Tenecteplase
Cerebral Infarction
Second Affiliated Hospital, School of Medicine, Zhejiang University
P3
BB
(65)
Eloxatin
Cancer of Colon
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
BB
(65)
Epirubicin
Breast Adenocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
BB
(65)
Nivolumab
Recurrent Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
BB
(65)
Nivolumab
Refractory Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
BB
(65)
Eloxatin
Colorectal Cancer Metastatic
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
BB
(64)
Recombinant Human Plasminogen Activator
Acute Ischemic Stroke (AIS)
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
BB
(64)
Recombinant Human Plasminogen Activator
Thrombosis
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
BB
(64)
Cyclophosphamide
Fallopian Tube Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
P3
BB
(64)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
ER Positive, HER2 Positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
BB
(64)
Catequentinib
Ovarian Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
B
(63)
Recombinant Human Plasminogen Activator
Anterior Circulation Brain Infarction
Second Affiliated Hospital, School of Medicine, Zhejiang University
P3
B
(63)
Inno-206
Efficacy
Second Affiliated Hospital, School of Medicine, Zhejiang University
P4
B
(62)
Showing 1 to 25 of 171 assets
Previous
Page 1 of 7
Next